VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

SABCS 2022 | ELEANOR interim analysis: real-world study of adjuvant neratinib in HER2+/HR+ early breast cancer

Rupert Bartsch, MD, Comprehensive Cancer Center Vienna, Vienna, shares the interim results of the prospective, observational Phase IV ELEANOR (NCT04388384) trial, designed to investigate real-world use of neratinib and its treatment management in patients in patients with HR-positive, HER2-overexpressing/amplified breast cancer stage I-III at high-risk for recurrence. Primary endpoint is the rate of patients’ adherence to neratinib treatment. Secondary objectives include characterization of patients scheduled to receive neratinib, details on neratinib treatment, recurrences, safety, and health-related quality of life (HRQoL). The Phase III ExteNET (NCT00878709) study had demonstrated an improved 5-year invasive disease-free survival (iDFS) rate by 5.1% versus placebo in this population and lead to approval of neratinib in Europe. Diarrhea, the most common grade 3 adverse event with neratinib. The ELEANOR trial saw a lower grade 3 diarrhea rate compared to ExteNET. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter